Adagene to Present at Leerink’s Global Healthcare Conference 2025
Adagene (Nasdaq: ADAG), a pioneer in antibody-based therapy development, has announced its participation in Leerink's Global Healthcare Conference 2025. The event will take place from March 10-12 in Miami, Florida.
Dr. Peter Luo, who serves as the company's Chairman, CEO, and President of R&D, will engage in one-on-one investor meetings and deliver a corporate presentation. The presentation is scheduled for Wednesday, March 12, from 10:40-11:20 AM Eastern Time at W South Beach.
Investors and interested parties can access the presentation webcast through the Investors section of Adagene's website (www.adagene.com), where it will remain available for a minimum of 30 days.
Adagene (Nasdaq: ADAG), un pioniere nello sviluppo di terapie basate sugli anticorpi, ha annunciato la sua partecipazione alla Global Healthcare Conference 2025 di Leerink. L'evento si terrà dal 10 al 12 marzo a Miami, Florida.
Il Dr. Peter Luo, che ricopre il ruolo di Presidente, CEO e Presidente della R&D dell'azienda, parteciperà a incontri individuali con gli investitori e presenterà un intervento aziendale. La presentazione è programmata per mercoledì 12 marzo, dalle 10:40 alle 11:20 AM ora orientale presso il W South Beach.
Investitori e parti interessate possono accedere alla diretta della presentazione tramite la sezione Investitori del sito web di Adagene (www.adagene.com), dove rimarrà disponibile per un minimo di 30 giorni.
Adagene (Nasdaq: ADAG), un pionero en el desarrollo de terapias basadas en anticuerpos, ha anunciado su participación en la Global Healthcare Conference 2025 de Leerink. El evento se llevará a cabo del 10 al 12 de marzo en Miami, Florida.
El Dr. Peter Luo, quien se desempeña como Presidente, CEO y Presidente de I+D de la empresa, participará en reuniones individuales con inversores y ofrecerá una presentación corporativa. La presentación está programada para el miércoles 12 de marzo, de 10:40 a 11:20 AM hora del Este en el W South Beach.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo de la presentación a través de la sección de Inversores del sitio web de Adagene (www.adagene.com), donde estará disponible durante un mínimo de 30 días.
Adagene (Nasdaq: ADAG), 항체 기반 치료 개발의 선구자로, Leerink의 글로벌 헬스케어 컨퍼런스 2025에 참여한다고 발표했습니다. 이 행사는 3월 10일부터 12일까지 플로리다주 마이애미에서 열립니다.
회사의 회장, CEO 및 R&D 사장인 Dr. Peter Luo는 개별 투자자 회의에 참여하고 기업 발표를 진행할 예정입니다. 발표는 3월 12일 수요일 오전 10:40부터 11:20까지 동부 표준시 기준으로 W South Beach에서 예정되어 있습니다.
투자자 및 관심 있는 분들은 Adagene 웹사이트(www.adagene.com)의 투자자 섹션을 통해 발표 웹캐스트에 접속할 수 있으며, 최소 30일 동안 이용 가능합니다.
Adagene (Nasdaq: ADAG), un pionnier dans le développement de thérapies basées sur les anticorps, a annoncé sa participation à la Global Healthcare Conference 2025 de Leerink. L'événement se déroulera du 10 au 12 mars à Miami, en Floride.
Le Dr. Peter Luo, qui occupe le poste de Président, CEO et Président de la R&D de l'entreprise, participera à des réunions individuelles avec des investisseurs et présentera une intervention d'entreprise. La présentation est prévue pour le mercredi 12 mars, de 10h40 à 11h20 heure de l'Est au W South Beach.
Les investisseurs et les parties intéressées peuvent accéder au webinaire de la présentation via la section Investisseurs du site web d'Adagene (www.adagene.com), où il restera disponible pendant un minimum de 30 jours.
Adagene (Nasdaq: ADAG), ein Pionier in der Entwicklung von Antikörper-basierten Therapien, hat seine Teilnahme an der Global Healthcare Conference 2025 von Leerink bekannt gegeben. Die Veranstaltung findet vom 10. bis 12. März in Miami, Florida, statt.
Dr. Peter Luo, der als Vorsitzender, CEO und Präsident der F&E des Unternehmens fungiert, wird an eins-zu-eins Investorenmeetings teilnehmen und eine Unternehmenspräsentation halten. Die Präsentation ist für Mittwoch, den 12. März, von 10:40 bis 11:20 Uhr Eastern Time im W South Beach geplant.
Investoren und Interessierte können über den Investorenbereich der Website von Adagene (www.adagene.com) auf den Webcast der Präsentation zugreifen, der mindestens 30 Tage lang verfügbar sein wird.
- None.
- None.
SAN DIEGO and SUZHOU, China, March 06, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in one-on-one investor meetings and provide a corporate update at Leerink’s Global Healthcare Conference 2025, taking place March 10-12 in Miami, Florida.
Leerink’s Global Healthcare Conference 2025
- Presentation Date: Wednesday, March 12
- Presentation Time: 10:40-11:20 AM (Eastern Time)
- Location: W South Beach
A webcast of the presentation will be accessible in the Investors section of the company’s website at https://www.adagene.com for at least 30 days.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody® precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and Twitter.
SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
Adagene
raymond_tam@adagene.com
Bruce Mackle
LifeSci Advisors
bmackle@lifesciadvisors.com
FAQ
When and where is Adagene (ADAG) presenting at Leerink's Global Healthcare Conference 2025?
How can investors access Adagene's (ADAG) Leerink Conference presentation?
What type of meetings will Adagene (ADAG) conduct at the Leerink Healthcare Conference?
Who will represent Adagene (ADAG) at the Leerink Global Healthcare Conference 2025?
